Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes
Launched by NOVO NORDISK A/S · Nov 4, 2011
Trial Information
Current as of June 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes for at least 24 months
- • Insulin treatment for the pase 3 months
- • HbA1c (glycosylated haemoglobin) below 13%
- • BMI (Body Mass Index) below 40 kg/m\^2
- • Ability and willingness to perform self-blood glucose monitoring
- Exclusion Criteria:
- • Receipt of any investigational drug within 4 weeks prior to this trial
- • Treatment of OHAs (Oral Hypoglycaemic Agents) within 4 weeks prior to this trial
- • Total daily insulin dosage less than or equal to 1.8 IU/kg
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
örebro, , Sweden
Esbjerg, , Denmark
Næstved, , Denmark
Bergen, , Norway
Oslo, , Norway
århus C, , Denmark
Viborg, , Denmark
Malmö, , Sweden
Bekkestua, , Norway
Tromsø, , Norway
Karlstad, , Sweden
Värnamo, , Sweden
Mölndal, , Sweden
Grästorp, , Sweden
Holbæk, , Denmark
Silkeborg, , Denmark
Härnösand, , Sweden
Göteborg, , Sweden
Herning, , Denmark
Randers, , Denmark
Skive, , Denmark
Haugesund, , Norway
Hønefoss, , Norway
Moelv, , Norway
Vennesla, , Norway
åsgårdstrand, , Norway
Arvika, , Sweden
Avesta, , Sweden
Bjuv, , Sweden
Broby, , Sweden
Färgelanda, , Sweden
Habo, , Sweden
Helsingborg, , Sweden
Hässleholm, , Sweden
Jönköping, , Sweden
Kristianstad, , Sweden
Kristinehamn, , Sweden
Kungsbacka, , Sweden
Mellerud, , Sweden
Norrköping, , Sweden
Skövde, , Sweden
Stockholm, , Sweden
Säffle, , Sweden
Tomelilla, , Sweden
Torsby, , Sweden
Trollhättan, , Sweden
Tyresö, , Sweden
Uddevalla, , Sweden
östersund, , Sweden
Patients applied
Trial Officials
Global Clinical Registry (GCR, 1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials